US-based biotechnology company Imunon has reported positive results from its Phase II OVATION 2 trial of IMNN-001 for ovarian ...

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response Results, presented simultaneously in oral ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Momentum Continues with Presentations at ASCO and ESMO Imunon, Inc.

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body's natural mechanisms to generate safe, effective and durable responses ...

IMUNON reports promising Phase 2 results for IMNN-001 in ovarian cancer, presenting at ASCO 2025 and publishing in Gynecologic Oncology. IMUNON, Inc. has announced significant progress in cancer ...

US Stocks Likely To Open Higher After S&P 500's Four-Day Fall: 'Market Is Risk-Off,' Says Expert U.S. stock futures rose on Tuesday after closing lower for the week on Friday. Futures of benchmark ...

Progress with IMNN-001: A Potential Game-Changer for Ovarian Cancer Over the past year, we have achieved remarkable milestones, most notably with our lead candidate, IMNN-001, which has entered ...

A New Jersey-based biotech company stole the show to finish out the week after the company announced new data from its Phase ...

LAWRENCEVILLE, N.J., April 21, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that an ...